Kura Oncology (NASDAQ:KURA) Research Coverage Started at UBS Group

UBS Group assumed coverage on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $27.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and cut their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Down 1.5 %

Shares of NASDAQ:KURA opened at $17.51 on Thursday. The firm has a market capitalization of $1.34 billion, a PE ratio of -7.85 and a beta of 0.84. Kura Oncology has a 1 year low of $7.52 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The firm’s 50-day moving average is $19.34 and its two-hundred day moving average is $20.09.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.53) EPS. Analysts predict that Kura Oncology will post -2.46 EPS for the current year.

Institutional Trading of Kura Oncology

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after buying an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Armistice Capital LLC increased its position in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Artal Group S.A. lifted its holdings in shares of Kura Oncology by 8.6% in the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock valued at $40,951,000 after purchasing an additional 151,828 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.